What Happened to Attention-Deficit/Hyperactivity Disorder?
Attention-Deficit/Hyperactivity Disorder (ADHD) has seen a dramatic increase in diagnoses, particularly among adults and women, driven by heightened awareness, reduced stigma, and expanded telehealth access. The landscape of ADHD treatment continues to evolve rapidly, with several new medications and FDA-approved digital therapeutics emerging between 2024 and 2026, alongside a growing emphasis on personalized and multimodal care.
Quick Answer
Attention-Deficit/Hyperactivity Disorder (ADHD) is experiencing a significant surge in diagnoses, especially in adults and women, largely due to increased public awareness and improved diagnostic tools. Recent years, up to September 2026, have brought several new FDA-approved medications like Onyda XR and Simtriyo, offering novel mechanisms of action. Additionally, prescription digital therapeutics are gaining traction as effective adjunct treatments, complementing traditional pharmacological and behavioral therapies in a move towards more personalized care.
📊Key Facts
📅Complete Timeline14 events
First descriptions of ADHD-like symptoms
Scottish physician Sir Alexander Crichton described 'the incapacity of attending with a necessary degree of constancy to any one object,' an early account of inattention symptoms.
Sir George Frederic Still's 'defect of moral control'
British pediatrician Sir George Frederic Still described children with 'an abnormal defect of moral control,' noting patterns of restless, inattentive, and overaroused behaviors.
Benzedrine's unexpected effects discovered
Dr. Charles Bradley observed that Benzedrine (an amphetamine) improved behavior and school performance in children, marking the accidental discovery of stimulant efficacy for hyperactivity.
FDA approves Ritalin (methylphenidate)
The psychostimulant methylphenidate, marketed as Ritalin, received FDA approval. It later became a widely used treatment for ADHD as the disorder became better understood.
ADD recognized in DSM-III
The American Psychiatric Association (APA) formally recognized 'Attention Deficit Disorder (ADD) with or without hyperactivity' in the third edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-III).
ADHD term introduced in DSM-III-R
The diagnostic label was refined to 'Attention-Deficit Hyperactivity Disorder (ADHD)' in the revised third edition of the DSM (DSM-III-R), consolidating the understanding of the disorder.
First non-stimulant medication, Strattera, approved
The FDA approved atomoxetine (Strattera), the first non-stimulant medication for ADHD, offering an alternative to traditional stimulants and the first approved for adults.
FDA approves Azstarys
Azstarys (serdexmethylphenidate prodrug plus dexmethylphenidate) received FDA approval, adding a new stimulant formulation to the ADHD pharmacopeia.
FDA approves Qelbree (viloxazine)
Qelbree (viloxazine) was FDA-approved for pediatric ADHD, and later for adult ADHD in April 2022, as a novel non-stimulant medication.
Vyvanse goes generic
Lisdexamfetamine (Vyvanse) received its first generic approval, significantly impacting the ADHD medication market by increasing accessibility.
FDA approves Onyda XR
Onyda XR (clonidine hydrochloride extended-release oral suspension) was FDA-approved as the first and only liquid extended-release non-stimulant for ADHD in patients aged 6 years and older.
FDA clears LumosityRx (PDT)
Lumos Labs obtained 510(k) clearance from the FDA for LumosityRx, a prescription digital therapeutic (PDT) for adults aged 22-55 with primarily inattentive or combined-type ADHD, marking a step forward for digital interventions.
FDA approves Simtriyo (centanafadine)
Otsuka Pharmaceutical announced FDA approval of SIMTRIYO® (centanafadine), a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD in adults and pediatric patients aged 6 years and older. Commercial availability is pending DEA scheduling.
Continued rise in ADHD prescriptions in England
Data from the NHS Business Services Authority showed a 12% increase in ADHD stimulant and drug prescriptions in England for April-June 2026 compared to the previous quarter, indicating ongoing growth in treatment.
Follow this story
Get an email when this timeline gets a major update.
🔍Deep Dive Analysis
Attention-Deficit/Hyperactivity Disorder (ADHD), a neurodevelopmental disorder characterized by persistent patterns of inattention and/or hyperactivity-impulsivity, has undergone significant shifts in understanding, diagnosis, and treatment in recent years. Historically, ADHD was often misconstrued as a childhood condition, but the period leading up to 2026 has seen a profound recognition of its persistence into adulthood and its varied presentations across genders. This evolving understanding has led to a notable surge in adult diagnoses, with over half (55.9%) of all adults with a current ADHD diagnosis receiving it in adulthood by 2023. Women, in particular, are now the fastest-growing demographic for new ADHD diagnoses, as increased awareness helps identify inattentive and internalizing symptoms previously overlooked.
Several converging factors explain this diagnostic surge. Greater public and clinician awareness, coupled with reduced stigma surrounding mental health, has encouraged more individuals to seek evaluation. Updated diagnostic criteria, which have expanded over the last decade, also play a role in accurately identifying more cases. The COVID-19 pandemic significantly impacted this trend, disrupting routines, exacerbating symptoms, and accelerating the adoption of telehealth services, which made mental health care more accessible. Social media has also contributed to increased awareness, though it has also raised concerns about misinformation and self-diagnosis.
The consequences of this increased identification are largely positive, leading to more individuals receiving needed support. However, challenges persist, notably the ongoing global medication shortages that have devastated continuity of care for many patients. Research in 2025 highlighted a significant 'longevity gap' for individuals with untreated ADHD, underscoring the life-saving potential of proper treatment, which can reduce the risk of premature death from unnatural causes.
As of September 2026, the treatment landscape for ADHD is more diverse and personalized than ever. While stimulant medications remain highly effective, new non-stimulant options have been introduced. Onyda XR (clonidine extended-release oral suspension) was FDA-approved in May 2024 as the first liquid extended-release non-stimulant for ADHD in patients aged 6 and older. A significant development in July 2026 was the FDA approval of Simtriyo (centanafadine), a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), offering a novel mechanism of action for adults and pediatric patients aged 6 and older. This medication is expected to be commercially available later in 2026 following DEA scheduling.
Beyond pharmacology, non-medication treatments are also advancing. Prescription digital therapeutics (PDTs) have emerged as a significant innovation, with products like LumosityRx receiving FDA clearance in December 2025 for adult ADHD, offering evidence-based cognitive training. These digital tools, along with refined behavioral therapies like Cognitive Behavioral Therapy (CBT) and specialized coaching, are integral to the multimodal approach increasingly favored by clinicians. The year 2026 has also seen the approval of ultra-long-acting stimulants and novel non-stimulants targeting different neurotransmitter pathways, alongside a growing trend towards personalized medicine utilizing AI and genetic testing to optimize treatment selection. This comprehensive approach aims to address the unique needs of individuals with ADHD, moving beyond a one-size-fits-all model.
What If...?
Explore alternate histories. What if Attention-Deficit/Hyperactivity Disorder made different choices?